References
- Tunca F, Sormaz IC, Iscan Y, Senyurek YG, Terzioglu T. Comparison of histopathological features and prognosis of classical and follicular variant papillary thyroid carcinoma. J Endocrinol Invest 2015;38:1327-1334. https://doi.org/10.1007/s40618-015-0376-6
- Oakley GM, Curtin K, Layfield L, Jarboe E, Buchmann LO, Hunt JP. Increased melanoma risk in individuals with papillary thyroid carcinoma. JAMA Otolaryngol Head Neck Surg 2014;140:423-427. https://doi.org/10.1001/jamaoto.2014.78
- Lloyd RV, Buehler D, Khanafshar E. Papillary thyroid carcinoma variants. Head Neck Pathol 2011;5:51-56. https://doi.org/10.1007/s12105-010-0236-9
- Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003;63:1454-1457.
- Ellerhorst JA, Sendi-Naderi A, Johnson MK, Cooke CP, Dang SM, Diwan AH. Human melanoma cells express functional receptors for thyroid-stimulating hormone. Endocr Relat Cancer 2006;13:1269-1277. https://doi.org/10.1677/erc.1.01239